

Chapter 4

REFERENCES

1. Collins FS, Green ED, Guttmacher AE, Guyer MS; US National Human Genome Research Institute. A vision for the future of genomics research. *Nature*. 2003;422:835-847.
2. Lunshof JE, Bobe J, Aach J, et al. Personal genomes in progress: from the human genome project to the personal genome project. *Dialogues Clin Neurosci*. 2010;12:47-60.
3. Podgoreanu MV, Schwinn DA. New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. *J Am Coll Cardiol*. 2005;46:1965-1977.
4. Fox AA, Shernan SK, Body SC. Predictive genomics of adverse events after cardiac surgery. *Semin Cardiothorac Vasc Anesth*. 2004;8:297-315.
5. Stuber F, Hoeft A. The influence of genomics on outcome after cardiovascular surgery. *Curr Opin Anaesthesiol*. 2002;15:3-8.
6. Ziegeler S, Tsusaki BE, Collard CD. Influence of genotype on perioperative risk and outcome. *Anesthesiology*. 2003;99:212-219.
7. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. *Nature*. 2006;444:444-454.
8. Levy S, Sutton G, Ng PC, et al. The diploid genome sequence of an individual human. *PLoS Biol*. 2007;5:e254.
9. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, et al. Localization of a susceptibility gene for common forms of stroke to 5q12. *Am J Hum Genet*. 2002;70:593-603.
10. Broeckel U, Hengstenberg C, Mayer B, et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. *Nat Genet*. 2002;30:210-214.
11. Zintzaras E, Kitsios G, Kent D, et al. Genome-wide scans meta-analysis for pulse pressure. *Hypertension*. 2007;50:557-564.
12. Risch N, Merikangas K. The future of genetic studies of complex human diseases. *Science*. 1996;273:1516-1517.
13. Tabor HK, Risch NJ, Myers RM. Opinion: Candidate-gene approaches for studying complex genetic traits: practical considerations. *Nat Rev Genet*. 2002;3:391-397.
14. Winkelmann BR, Hager J. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. *Pharmacogenomics*. 2000;1:73-94.
15. Agema WR, Jukema JW, Pimstone SN, Kastelein JJ. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. *Eur Heart J*. 2001;22:2058-2074.
16. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. *Nat Genet*. 2002;32:650-654.
17. Podgoreanu MV, White WD, Morris RW, et al. Inflammatory gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. *Circulation*. 2006;114:1275-1281.
18. Collard CD, Shernan SK, Fox AA, et al. The MBL2 ϵ LYQA secretor' haplotype is an independent predictor of postoperative myocardial infarction in whites undergoing coronary artery bypass graft surgery. *Circulation*. 2007;116:1106-1112.
19. Tardiff BE, Newman MF, Saunders AM, et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. *Ann Thorac Surg*. 1997;64:715-720.
20. Mathew JP, Rinder CS, Howe JG, et al. Platelet P1A2 polymorphism enhances risk of neurocognitive decline after cardiopulmonary bypass. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. *Ann Thorac Surg*. 2001;71:663-666.
21. Mathew JP, Podgoreanu MV, Grocott HP, et al. Genetic variants in P-selectin and C-reactive protein influence susceptibility to cognitive decline after cardiac surgery. *J Am Coll Cardiol*. 2007;49:1934-1942.
22. Stafford-Smith M, Podgoreanu M, Swaminathan M, et al. Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. *Am J Kidney Dis*. 2005;45:519-530.
23. Chew ST, Newman MF, White WD, et al. Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. *Anesthesiology*. 2000;93:325-331.
24. MacKensen GB, Swaminathan M, Ti LK, et al. Preliminary report on the interaction of apolipoprotein E polymorphism with aortic atherosclerosis and acute nephropathy after CABG. *Ann Thorac Surg*. 2004;78:520-526.
25. Ortlepp JR, Janssens U, Bleckmann F, et al. A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts. *Coron Artery Dis*. 2001;12:493-497.
26. Ellis SG, Chen MS, Jia G, Luke M, Cassano J, Lytle B. Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency. *Am J Cardiol*. 2007;99:1087-1089.
27. Donahue BS. Factor V Leiden and perioperative risk. *Anesth Analg*. 2004;98:1623-1634; table of contents.
28. Lasocki S, Iglarz M, Seince PF, et al. Involvement of renin-angiotensin system in pressure-flow relationship: role of angiotensin-converting enzyme gene polymorphism. *Anesthesiology*. 2002;96:271-275.

29. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor- α concentrations and outcome of patients with severe sepsis. *Crit Care Med*. 1996;24:381-384.
30. Moretti EW, Morris RW, Podgoreanu M, et al. APOE polymorphism is associated with risk of severe sepsis in surgical patients. *Crit Care Med*. 2005;33:2521-2526.
31. Slavcheva E, Albanis E, Jiao Q, et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to acute allograft rejection. *Transplantation*. 2001;72:935-940.
32. Cardon LR, Bell JI. Association study designs for complex diseases. *Nat Rev Genet*. 2001;2:91-99.
33. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. *Genet Med*. 2002;4:45-61.
34. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. *Nat Genet*. 2003;33:177-182.
35. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature*. 2007;449:851-861.
36. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007;447:661-678.
37. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. *N Engl J Med*. 2007;357:443-453.
38. McPherson R, Pertsemlidis A, Kavasslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. *Science*. 2007;316:1488-1491.
39. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science*. 2007;316:1491-1493.
40. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet*. 2007;39:857-864.
41. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science*. 2007;316:1331-1336.
42. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature*. 2007;448:353-357.
43. National Human Genome Research Institute. *A Catalogue of Published Genome-Wide Association Studies*. <http://www.genome.gov/gwastudies>. Bethesda, MD. Accessed December 10, 2010.
44. Preuss M, König IR, Thompson JR, et al. Design of the Coronary ARtery Disease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. *Circ Cardiovasc Genet*. 2010;3:475-483.
45. Feero WG, Guttmacher AE, Collins FS. Genomic medicine—an updated primer. *N Engl J Med*. 2010;362:2001-2011.
46. Wheeler DA, Srinivasan M, Egholm M, et al. The complete genome of an individual by massively parallel DNA sequencing. *Nature*. 2008;452:872-876.
47. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. *Lancet*. 2010;375:1525-1535.
48. Venter JC. Multiple personal genomes await. *Nature*. 2010;464:676-677.
49. Stranger BE, Nica AC, Forrest MS, et al. Population genomics of human gene expression. *Nat Genet*. 2007;39:1217-1224.
50. Hopf HW. Molecular diagnostics of injury and repair responses in critical illness: what is the future of “monitoring” in the intensive care unit? *Crit Care Med*. 2003;31:S518-S523.
51. Feezor RJ, Baker HV, Xiao W, et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. *J Immunol*. 2004;172:7103-7109.
52. Hughes TR, Marton MJ, Jones AR, et al. Functional discovery via a compendium of expression profiles. *Cell*. 2000;102:109-126.
53. Tomic V, Russwurm S, Möller E, et al. Transcriptomic and proteomic patterns of systemic inflammation in on-pump and off-pump coronary artery bypass grafting. *Circulation*. 2005;112:2912-2920.
54. Sehl PD, Tai JT, Hillan KJ, et al. Application of cDNA microarrays in determining molecular phenotype in cardiac growth, development, and response to injury. *Circulation*. 2000;101:1990-1999.
55. Depre C, Tomlinson JE, Kudej RK, et al. Gene program for cardiac cell survival induced by transient ischemia in conscious pigs. *Proc Natl Acad Sci U S A*. 2001;98:9336-9341.
56. Ruel M, Bianchi C, Khan TA, et al. Gene expression profile after cardiopulmonary bypass and cardioplegic arrest. *J Thorac Cardiovasc Surg*. 2003;126:1521-1530.
57. Konstantinov IE, Coles JG, Boscarino C, et al. Gene expression profiles in children undergoing cardiac surgery for right heart obstructive lesions. *J Thorac Cardiovasc Surg*. 2004;127:746-754.
58. Sergeev P, da Silva R, Lucchinetti E, Zaugg K, Pasch T, Schaub MC, Zaugg M. Trigger-dependent gene expression profiles in cardiac preconditioning: evidence for distinct genetic programs in ischemic and anesthetic preconditioning. *Anesthesiology*. 2004;100:474-488.
59. Lucchinetti E, Aguirre J, Feng J, et al. Molecular evidence of late preconditioning after sevoflurane inhalation in healthy volunteers. *Anesth Analg*. 2007;105:629-640.
60. Lucchinetti E, Hofer C, Bestmann L, et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. *Anesthesiology*. 2007;106:444-457.
61. Atkins JH, Johansson JS. Technologies to shape the future: proteomics applications in anesthesiology and critical care medicine. *Anesth Analg*. 2006;102:1207-1216.
62. Futterer CD, Maurer MH, Schmitt A, Feldmann RE Jr, Kuschinsky W, Waschke KF. Alterations in rat brain proteins after desflurane anesthesia. *Anesthesiology*. 2004;100:302-308.
63. Kalenka A, Hinkelbein J, Feldmann RE Jr, et al. The effects of sevoflurane anesthesia on rat brain proteins: a proteomic time-course analysis. *Anesth Analg*. 2007;104:1129-1135; tables of contents.
64. Sheikh AM, Barrett C, Villamizar N, et al. Proteomics of cerebral injury in a neonatal model of cardiopulmonary bypass with deep hypothermic circulatory arrest. *J Thorac Cardiovasc Surg*. 2006;132:820-828.
65. Queloz PA, Thadikkaran L, Crettaz D, Rossier JS, Barelli S, Tissot JD. Proteomics and transfusion medicine: future perspectives. *Proteomics*. 2006;6:5605-5614.

66. Lewis GD, Wei R, Liu E, et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. *J Clin Invest*. 2008;118:3503-3512.
67. Turer AT, Stevens RD, Bain JR, et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. *Circulation*. 2009;119:1736-1746.
68. Mayr M, Yusuf S, Weir G, et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. *J Am Coll Cardiol*. 2008;51:585-594.
69. Mangano DT. Perioperative medicine: NHLBI working group deliberations and recommendations. *J Cardiothorac Vasc Anesth*. 2004;18:1-6.
70. Howell SJ, Sear JW. Perioperative myocardial injury: individual and population implications. *Br J Anaesth*. 2004;93:3-8.
71. Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. *JAMA*. 1997;277:325-332.
72. Mahaffey KW, Roe MT, Kilaru R, et al. Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. *Eur Heart J*. 2007;28:425-432.
73. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. *Circulation*. 2009;119:2936-2944.
74. Delanghe J, Cambier B, Langlois M, et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. *Atherosclerosis*. 1997;132:215-219.
75. Volzke H, Engel J, Kleine V, Schwahn C, Dahm JB, Eckel L, Rettig R. Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. *Chest*. 2002;122:31-36.
76. Shaw AD, Vaporciyan AA, Wu X, et al. Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. *Ann Thorac Surg*. 2005;79:1704-1710.
77. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. *Arterioscler Thromb Vasc Biol*. 2001;21:1458-1463.
78. Burzotta F, Iacoviello L, Di Castelnuovo A, et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. *Am J Cardiol*. 2001;88:1125-1128.
79. Grocott HP, Newman MF, El-Moalem H, Bainbridge D, Butler A, Laskowitz DT. Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. *J Thorac Cardiovasc Surg*. 2001;122:622-623.
80. Roth-Isigkeit A, Hasselbach L, Ocklitz E, et al. Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass. *Clin Exp Immunol*. 2001;125:80-88.
81. Tomasdottir H, Hjartarson H, Ricksten A, et al. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. *Anesth Analg*. 2003;97:944-949; table of contents.
82. Lehmann LE, Schroeder S, Hartmann W, et al. A single nucleotide polymorphism of macrophage migration inhibitory factor is related to inflammatory response in coronary bypass surgery using cardiopulmonary bypass. *Eur J Cardiothorac Surg*. 2006;30:59-63.
83. Galley HF, Lowe PR, Carmichael RL, Webster NR. Genotype and interleukin-10 responses after cardiopulmonary bypass. *Br J Anaesth*. 2003;91:424-426.
84. Stoica AL, Stoica E, Constantinescu I, Uscatescu V, Ginghina C. Interleukin-6 and interleukin-10 gene polymorphism, endothelial dysfunction, and postoperative prognosis in patients with peripheral arterial disease. *J Vasc Surg*. 2010;52:103-109.
85. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. *Circulation*. 2004;109:II2-10.
86. Perry TE, Muehlschlegel JD, Liu KY, et al. Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting. *Anesthesiology*. 2010;112:607-613.
87. Kangasniemi OP, Biancari F, Luukkonen J, et al. Preoperative C-reactive protein is predictive of long-term outcome after coronary artery bypass surgery. *Eur J Cardiothorac Surg*. 2006;29:983-985.
88. Song Y, Kwak YL, Choi YS, Kim JC, Heo SB, Shim JK. Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level. *Korean J Anesthesiol*. 2010;58:136-141.
89. Choi JH, Cho DK, Song YB, et al. Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. *Heart*. 2010;96:56-62.
90. Perry TE, Muehlschlegel JD, Liu KY, et al. C-reactive protein gene variants are associated with postoperative C-reactive protein levels after coronary artery bypass surgery. *BMC Med Genet*. 2009;10:38.
91. Motoyama S, Miura M, Hinai Y, et al. C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer. *J Am Coll Surg*. 2009;209:477-483.
92. Motoyama S, Miura M, Hinai Y, Maruyama K, Murata K, Ogawa J. C-reactive protein -717C>T genetic polymorphism associates with esophagectomy-induced stress hyperglycemia. *World J Surg*. 2010;34:1001-1007.
93. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. *Arterioscler Thromb Vasc Biol*. 2004;24:216-229.
94. Rifon J, Paramo JA, Panizo C, et al. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. *Br J Haematol*. 1997;99:262-267.
95. Iacoviello L, Burzotta F, Di Castelnuovo A, et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. *Thromb Haemost*. 1998;80:1029-1030.
96. Rinder CS, Mathew JP, Rinder HM, et al. Platelet PIA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. *Anesthesiology*. 2002;97:1118-1122.
97. Zotz RB, Klein M, Dauben HP, Moser C, Gams E, Scharf R. Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death. *Thromb Haemost*. 2000;83:404-407.

98. Faraday N, Martinez EA, Scharpf RB, et al. Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. *Anesthesiology*. 2004;101:1291-1297.
99. Donahue BS, Gailani D, Higgins MS, et al. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. *Circulation*. 2003;107:1003-1008.
100. Moor E, Silveira A, van't Hooff F, et al. Coagulation factor V (Arg506-->Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting. *Thromb Haemost*. 1998;80:220-224.
101. Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. *J Am Coll Cardiol*. 2009;54:1599-1606.
102. Ryding AD, Kumar S, Worthington AM, Burgess D. Prognostic value of brain natriuretic peptide in noncardiac surgery: a meta-analysis. *Anesthesiology*. 2009;111:311-319.
103. Fox AA, Shernan SK, Collard CD, et al. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. *J Thorac Cardiovasc Surg*. 2008;136:452-461.
104. Fox AA, Muehlschlegel JD, Body SC, et al. Comparison of the utility of preoperative versus postoperative B-type natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting. *Anesthesiology*. 2010;112:842-851.
105. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. *Eur Heart J*. 2009;30:2769-2812.
106. Shaw SM, Lewis NT, Williams SG, Tan LB. A role for BNP assays in monitoring aortic valve disease for optimal timing of surgery. *Int J Cardiol*. 2008;127:328-330.
107. Fox AA, Collard CD, Shernan SK, et al. Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. *Anesthesiology*. 2009;110:738-747.
108. Zaugg M, Schaub MC. Genetic modulation of adrenergic activity in the heart and vasculature: implications for perioperative medicine. *Anesthesiology*. 2005;102:429-446.
109. Zaugg M, Bestmann L, Wacker J, et al. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. *Anesthesiology*. 2007;107:33-44.
110. Philip I, Plantefevre G, Vuillaumier-Barrot S, et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. *Circulation*. 1999;99:3096-3098.
111. Henrion D, Benessiano J, Philip I, et al. The deletion genotype of the angiotensin I-converting enzyme is associated with an increased vascular reactivity in vivo and in vitro. *J Am Coll Cardiol*. 1999;34:830-836.
112. Kim NS, Lee IO, Lee MK, et al. The effects of beta2 adrenoceptor gene polymorphisms on pressor response during laryngoscopy and tracheal intubation. *Anaesthesia*. 2002;57:227-232.
113. Smiley RM, Blouin JL, Negron M, Landau R. Beta2-adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery. *Anesthesiology*. 2006;104:644-650.
114. Ryan R, Thornton J, Duggan E, et al. Gene polymorphism and requirement for vasopressor infusion after cardiac surgery. *Ann Thorac Surg*. 2006;82:895-901.
115. Liu KY, Muehlschlegel JD, Perry TE, et al. Common genetic variants on chromosome 9p21 predict perioperative myocardial injury after coronary artery bypass graft surgery. *J Thorac Cardiovasc Surg*. 2010;139:483-438, 488.e1-2.
116. Muehlschlegel JD, Liu KY, Perry TE, et al. Chromosome 9p21 variant predicts mortality after coronary artery bypass graft surgery. *Circulation*. 2010;122:S60-S65.
117. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. *JAMA*. 2004;291:1720-1729.
118. Brugada R. Is atrial fibrillation a genetic disease? *J Cardiovasc Electrophysiol*. 2005;16:553-556.
119. Body SC, Collard CD, Shernan SK, et al. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. *Circ Cardiovasc Genet*. 2009;2:499-506.
120. Gaudino M, Andreotti F, Zamparelli R, et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? *Circulation*. 2003;108 Suppl 1:II195-9.
121. Gaudino M, Di Castelnuovo A, Zamparelli R, et al. Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. *J Thorac Cardiovasc Surg*. 2003;126:1107-1112.
122. Motsinger AA, Donahue BS, Brown NJ, et al. Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. *Pac Symp Biocomput*. 2006:584-595.
123. Hogue CW Jr, Palin CA, Kailasam R, et al. C-reactive protein levels and atrial fibrillation after cardiac surgery in women. *Ann Thorac Surg*. 2006;82:97-102.
124. Pretorius M, Donahue BS, Yu C, et al. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. *Circulation*. 2007;116:11-7.
125. Barth AS, Merk S, Arnoldi E, et al. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. *Circ Res*. 2005;96:1022-1029.
126. Ramlawi B, Otu H, Mieno S, et al. Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. *Ann Thorac Surg*. 2007;84:1166-1172; discussion 1172-1173.
127. Mehra MR, Feller E, Rosenberg S. The promise of protein-based and gene-based clinical markers in heart transplantation: from bench to bedside. *Nat Clin Pract Cardiovasc Med*. 2006;3:136-143.
128. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. *N Engl J Med*. 2010;362:1890-1900.
129. Hall JL, Birks EJ, Grindle S, et al. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. *Eur Heart J*. 2007;28:613-627.
130. Matkovich SJ, Van Booven DJ, Youker KA, et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. *Circulation*. 2009;119:1263-1271.

131. Podgoreanu MV, Booth JV, White WD, et al. Beta adrenergic receptor polymorphisms and risk of adverse events following cardiac surgery. *Circulation*. 2003;108:IV-434.
132. Lobato RL, White WD, Mathew JP, et al. Thrombomodulin variants are associated with increased mortality following CABG surgery in replicated analyses. *Circulation*. 2010;122:A13651 (abstract).
133. Grocott HP, White WD, Morris RW, et al. Genetic polymorphisms and the risk of stroke after cardiac surgery. *Stroke*. 2005;36:1854-1858.
134. Newman MF, Booth JV, Laskowitz DT, et al. Genetic predictors of perioperative neurological and cognitive injury and recovery. *Best Pract Res Clin Anesthesiol*. 2001;15:247-276.
135. Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral haemorrhage. *Lancet*. 1995;346:575.
136. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. *Lancet*. 1997;350:1069-1071.
137. Slooter AJ, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. *JAMA*. 1997;277:818-821.
138. Sheng H, Laskowitz DT, Bennett E, et al. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. *J Cereb Blood Flow Metab*. 1998;18:361-366.
139. Leung JM, Sands LP, Wang Y, et al. Apolipoprotein E e4 allele increases the risk of early postoperative delirium in older patients undergoing noncardiac surgery. *Anesthesiology*. 2007;107:406-411.
140. Ely EW, Girard TD, Shintani AK, et al. Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients. *Crit Care Med*. 2007;35:112-117.
141. Gaynor JW, Gerdes M, Zackai EH, et al. Apolipoprotein E genotype and neurodevelopmental sequelae of infant cardiac surgery. *J Thorac Cardiovasc Surg*. 2003;126:1736-1745.
142. Zeltser I, Jarvik GP, Bernbaum J, et al. Genetic factors are important determinants of neurodevelopmental outcome after repair of tetralogy of Fallot. *J Thorac Cardiovasc Surg*. 2008;135:91-97.
143. Ti LK, Mathew JP, Mackensen GB, et al. Effect of apolipoprotein E genotype on cerebral autoregulation during cardiopulmonary bypass. *Stroke*. 2001;32:1514-1519.
144. Ti LK, Mackensen GB, Grocott HP, et al. Apolipoprotein E4 increases aortic atheroma burden in cardiac surgical patients. *J Thorac Cardiovasc Surg*. 2003;125:211-213.
145. Newman MF, Laskowitz DT, White WD, et al. Apolipoprotein E polymorphisms and age at first coronary artery bypass graft. *Anesth Analg*. 2001;92:824-829.
146. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. *N Engl J Med*. 1996;334:1090-1094.
147. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. *Arterioscler Thromb Vasc Biol*. 1998;18:1124-1131.
148. Ramlawi B, Otu H, Rudolph JL, et al. Genomic expression pathways associated with brain injury after cardiopulmonary bypass. *J Thorac Cardiovasc Surg*. 2007;134:996-1005.
149. Ramlawi B, Rudolph JL, Mieno S, et al. C-Reactive protein and inflammatory response associated to neurocognitive decline following cardiac surgery. *Surgery*. 2006;140:221-226.
150. Ramlawi B, Rudolph JL, Mieno S, et al. Serologic markers of brain injury and cognitive function after cardiopulmonary bypass. *Ann Surg*. 2006;244:593-601.
151. Heider P, Poppert H, Wolf O, et al. Fibrinogen and high-sensitive C-reactive protein as serologic predictors for perioperative cerebral microembolic lesions after carotid endarterectomy. *J Vasc Surg*. 2007;46:449-454.
152. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. *Ann Intern Med*. 1998;128:194-203.
153. Yende S, Wunderink R. Causes of prolonged mechanical ventilation after coronary artery bypass surgery. *Chest*. 2002;122:245-252.
154. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest*. 1990;86:1343-1346.
155. Yende S, Quasney MW, Tolley EA, Wunderink RG. Clinical relevance of angiotensin-converting enzyme gene polymorphisms to predict risk of mechanical ventilation after coronary artery bypass graft surgery. *Crit Care Med*. 2004;32:922-927.
156. Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 2002;166:646-650.
157. Yende S, Quasney MW, Tolley E, Zhang Q, Wunderink RG. Association of tumor necrosis factor gene polymorphisms and prolonged mechanical ventilation after coronary artery bypass surgery. *Crit Care Med*. 2003;31:133-140.
158. Roden DM. Cardiovascular pharmacogenomics. *Circulation*. 2003;108:3071-3074.
159. Lehmann H, Ryan E. The familial incidence of low pseudocholinesterase level. *Lancet*. 1956;271:124.
160. Bukaveckas BL, Valdes R Jr, Linder MW. Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. *J Cardiothorac Vasc Anesth*. 2004;18:353-365.
161. McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. *Nature*. 1990;343:562-564.
162. Pessah IN, Allen PD. Malignant hyperthermia. *Best Pract Res Clin Anesthesiol*. 2001;15:277-288.
163. Eger EI 2nd. *Anesthetic Uptake and Action*. Baltimore, MD: Williams and Wilkins; 1974.
164. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. *Anesthesiology*. 2004;101:279-283.
165. Ezri T, Sessler D, Weisenberg M, et al. Association of ethnicity with the minimum alveolar concentration of sevoflurane. *Anesthesiology*. 2007;107:9-14.
166. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. *Nature*. 1994;367:607-614.
167. Sonner JM, Antognini JF, Dutton RC, et al. Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. *Anesth Analg*. 2003;97:718-740.
168. Wong SM, Cheng G, Homanics GE, Kendig JJ. Enflurane actions on spinal cords from mice that lack the beta3 subunit of the GABA(A) receptor. *Anesthesiology*. 2001;95:154-164.
169. Homanics GE, Ferguson C, Quinlan JJ, et al. Gene knockout of the alpha6 subunit of the gamma-aminobutyric acid type A

- receptor: lack of effect on responses to ethanol, pentobarbital, and general anesthetics. *Mol Pharmacol*. 1997;51:588-596.
170. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. *Nature*. 1999;401:796-800.
 171. Belelli D, Lambert JJ, Peters JA, Wafford K, Whiting PJ. The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. *Proc Natl Acad Sci U S A*. 1997;94:11031-11036.
 172. Jurd R, Arras M, Lambert S, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. *FASEB J*. 2003;17:250-252.
 173. Reynolds DS, Rosahl TW, Cirone J, et al. Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. *J Neurosci*. 2003;23:8608-8617.
 174. Cirone J, Rosahl TW, Reynolds DS, et al. Gamma-aminobutyric acid type A receptor beta 2 subunit mediates the hypothermic effect of etomidate in mice. *Anesthesiology*. 2004;100:1438-1445.
 175. Lakhilani PP, MacMillan LB, Guo TZ, et al. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. *Proc Natl Acad Sci U S A*. 1997;94:9950-9955.
 176. Gerstin KM, Gong DH, Abdallah M, et al. Mutation of KCNK5 or Kir3.2 potassium channels in mice does not change minimum alveolar anesthetic concentration. *Anesth Analg*. 2003;96:1345-1349; table of contents.
 177. Sternberg WF, Mogil JF. Genetic and hormonal basis of pain states. *Best Pract Res Clin Anesthesiol*. 2001;15:229-245.
 178. Diatchenko L, Anderson AD, Slade GD, et al. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2006;141:449-462.
 179. Diatchenko L, Nackley AG, Tchivileva IE, Shabalina SA, Maixner W. Genetic architecture of human pain perception. *Trends Genet*. 2007;23:605-613.
 180. Bengtsson B, Thorson J. Back pain: a study of twins. *Acta Genet Med Gemellol (Roma)*. 1991;40:83-90.
 181. Mogil JS, Wilson SG, Bon K, et al. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. *Pain*. 1999;80:67-82.
 182. Lacroix-Fralish ML, Ledoux JB, Mogil JS. The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. *Pain*. 2007;131:3.e1-4.
 183. Somogyi AA, Barratt DT, Collier JK. Pharmacogenetics of opioids. *Clin Pharmacol Ther*. 2007;81:429-444.
 184. Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. *Pain*. 2006;125:216-224.
 185. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? *Anesthesiology*. 2005;102:543-549.
 186. Strange K. The end of "naive reductionism": rise of systems biology or renaissance of physiology? *Am J Physiol Cell Physiol*. 2005;288:C968-C974.
 187. Ge H, Walhout AJ, Vidal M. Integrating 'omic' information: a bridge between genomics and systems biology. *Trends Genet*. 2003;19:551-560.
 188. Lusis AJ. A thematic review series: systems biology approaches to metabolic and cardiovascular disorders. *J Lipid Res*. 2006;47:1887-1890.
 189. Shaw A. Exploring the periopome: the role of genomics in thoracic surgery and anaesthesia. *Curr Opin Anaesthesiol*. 2007;20:32-36.
 190. Khoury MJ, Yang Q, Gwinn M, Little J, Dana Flanders W. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. *Genet Med*. 2004;6:38-47.
 191. Hakonarson H, Thorvaldsson S, Helgadóttir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. *JAMA*. 2005;293:2245-2256.
 192. Phimister EG. Medicine and the racial divide. *N Engl J Med*. 2003;348:1081-1082.
 193. Raney BJ, Cline MS, Rosenbloom KR, et al. ENCODE whole-genome data in the UCSC genome browser (2011 update). *Nucleic Acids Res*. 2011;39:D871-D875.
 194. Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH Roadmap Epigenomics Mapping Consortium. *Nat Biotechnol*. 2010;28:1045-1048.
 195. Durbin RM, Abecasis GR, Altshuler DL, et al. A map of human genome variation from population-scale sequencing. *Nature*. 2010;467:1061-1073.
 196. Lucchinetti E, da Silva R, Pasch T, et al. Anaesthetic preconditioning but not postconditioning prevents early activation of the deleterious cardiac remodelling programme: evidence of opposing genomic responses in cardioprotection by pre- and postconditioning. *Br J Anaesth*. 2005;95:140-152.
 197. Lai LP, Lin JL, Lin CS, et al. Functional genomic study on atrial fibrillation using cDNA microarray and two-dimensional protein electrophoresis techniques and identification of the myosin regulatory light chain isoform reprogramming in atrial fibrillation. *J Cardiovasc Electrophysiol*. 2004;15:214-223.
 198. Horwitz PA, Tsai EJ, Putt ME, et al. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. *Circulation*. 2004;110:3815-3821.
 199. Borozdenkova S, Westbrook JA, Patel V, et al. Use of proteomics to discover novel markers of cardiac allograft rejection. *J Proteome Res*. 2004;3:282-288.
 200. Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. *Ann Intern Med*. 2010;153:425-434.
 201. Heusch G, Erbel R, Siffert W. Genetic determinants of coronary vasomotor tone in humans. *Am J Physiol Heart Circ Physiol*. 2001;281:H1465-H1468.
 202. Iribarren JL, Sagasti FM, Jimenez JJ, et al. TNFbeta+250 polymorphism and hyperdynamic state in cardiac surgery with extracorporeal circulation. *Interact Cardiovasc Thorac Surg*. 2008;7:1071-1074.
 203. Donahue BS, Roden D. Inflammatory cytokine polymorphisms are associated with beta-blocker failure in preventing postoperative atrial fibrillation. *Anesth Analg*. 2005;100:SCA30 (abstract).
 204. Podgoreanu MV, Morris R, Zhang Q, et al. Gene variants in Interleukin 1-beta are associated with early QTc prolongation after cardiac surgery. *Anesthesiology*. 2007;107:A1287 (abstract).

205. Botto N, Andreassi MG, Rizza A, et al. C677T polymorphism of the methylenetetrahydrofolate reductase gene is a risk factor of adverse events after coronary revascularization. *Int J Cardiol.* 2004;96:341-345.
206. Taylor KD, Scheuner MT, Yang H, et al. Lipoprotein lipase locus and progression of atherosclerosis in coronary-artery bypass grafts. *Genet Med.* 2004;6:481-486.
207. Holweg CT, Weimar W, Uitterlinden AG, Baan CC. Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. *J Heart Lung Transplant.* 2004;23:1017-1026.
208. Borozdenkova S, Smith J, Marshall S, et al. Identification of ICAM-1 polymorphism that is associated with protection from transplant associated vasculopathy after cardiac transplantation. *Hum Immunol.* 2001;62:247-255.
209. Vamvakopoulos JE, Taylor CJ, Green C, et al. Interleukin 1 and chronic rejection: possible genetic links in human heart allografts. *Am J Transplant.* 2002;2:76-83.
210. Benza RL, Coffey CS, Pekarek DM, et al. Transforming growth factor-beta polymorphisms and cardiac allograft rejection. *J Heart Lung Transplant.* 2009;28:1057-1062.
211. McDonagh DL, Mathew JP, White WD, et al. Cognitive function after major noncardiac surgery, apolipoprotein E4 genotype, and biomarkers of brain injury. *Anesthesiology.* 2010;112:852-859.
212. Duggan E, O'Dwyer MJ, Caraher E, et al. Coagulopathy after cardiac surgery may be influenced by a functional plasminogen activator inhibitor polymorphism. *Anesth Analg.* 2007;104:1343-1347.
213. Welsby IJ, Podgoreanu MV, Phillips-Bute B, et al. Genetic factors contribute to bleeding after cardiac surgery. *J Thromb Haemost.* 2005;3:1206-1212.
214. Morawski W, Sanak M, Cisowski M, et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. *J Thorac Cardiovasc Surg.* 2005;130:791-796.
215. Achrol AS, Kim H, Pawlikowska L, et al. Association of tumor necrosis factor-alpha-238G>A and apolipoprotein E2 polymorphisms with intracranial hemorrhage after brain arteriovenous malformation treatment. *Neurosurgery.* 2007;61:731-739; discussion 740.
216. Welsby IJ, Podgoreanu MV, Phillips-Bute B, et al. Association of the 98T ELAM-1 polymorphism with increased bleeding after cardiac surgery. *J Cardiothorac Vasc Anesth.* 2010;24:427-433.